NCT06315699View on ClinicalTrials.gov

Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

March 2, 2025

Study Completion Date

December 30, 2025

Conditions
Williams SyndromeChildNeurodevelopmental Delay
Interventions
DRUG

Clemastine Fumarate Tablets

The dose was administered 2mg once daily in a double-blind random crossover method

DIETARY_SUPPLEMENT

fructose

The dose was administered 2mg once daily in a double-blind random crossover method

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Tainan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER